Drugs / XS228CN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07118319 | Sep 2025 → Jan 2027 expected | amyotrophic lateral sclerosis | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS228CN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07118319 ↗ |
| Modality | Cell therapy | “Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)” NCT07118319 ↗ |
| Route | Intrathecal | “intrathecal injection” NCT07118319 ↗ |